CIP2A mediates prostate cancer progression via the c-MYC signaling pathway. (Q51020266)

27 March 2018

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

CIP2A mediates prostate cancer progression via the c-MYC signaling pathway. (English)

1 reference

27 March 2018

author name string

Zexiong Guo

series ordinal

1

1 reference

27 March 2018

Dehao Liu

series ordinal

2

1 reference

27 March 2018

Zexuan Su

series ordinal

3

1 reference

27 March 2018

publication date

6 January 2015

1 reference

27 March 2018

published in

Tumor Biology

1 reference

27 March 2018

volume

36

1 reference

27 March 2018

issue

5

1 reference

27 March 2018

page(s)

3583-3589

1 reference

27 March 2018

https://scigraph.springernature.com/pub.10.1007/s13277-014-2995-5

exact match

0 references

cites work

Estimates of cancer incidence and mortality in Europe in 2008.

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2995-5

Prostate cancer research in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2995-5

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2995-5

The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2995-5

Emerging therapies in castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2995-5

MYC-dependent regulation and prognostic role of CIP2A in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2995-5

CIP2A is associated with human breast cancer aggressivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2995-5

Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2995-5

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2995-5

CIP2A influences survival in colon cancer and is critical for maintaining Myc expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2995-5

Prognostic role of CIP2A expression in serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2995-5

Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2995-5

CIP2A inhibits PP2A in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2995-5

A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-014-2995-5

CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25560487

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S13277-014-2995-5

1 reference

27 March 2018

1 reference

27 March 2018